scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update
November 13, 2024 16:01 ET
|
scPharmaceuticals Inc.
Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive...
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
November 06, 2024 16:01 ET
|
scPharmaceuticals Inc.
BURLINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric...
scPharmaceuticals Inc. to Present at the Jefferies 2019 London Healthcare Conference
November 14, 2019 08:00 ET
|
scPharmaceuticals Inc.
BURLINGTON, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
November 12, 2019 08:00 ET
|
scPharmaceuticals Inc.
Continued progress on FUROSCIX®; confirming the planned resubmission of FUROSCIX® NDA with the FDA by mid-year 2020 remains on track Company initiated the second of two planned human factors studies ...
scPharmaceuticals Inc. Provides FUROSCIX® Update and Announces Completion of $20.0 Million Term Loan Agreement
September 18, 2019 08:00 ET
|
scPharmaceuticals Inc.
Continued progress on FUROSCIX; confirming the planned resubmission of FUROSCIX NDA with the FDA by mid-year 2020 Completed $20.0 Million Term Loan with Solar Capital Ltd. and Silicon Valley Bank ...
scPharmaceuticals Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
August 07, 2019 08:00 ET
|
scPharmaceuticals Inc.
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission Company successfully completed the first...
scPharmaceuticals Inc. to Present at the 2019 Wedbush PacGrow Healthcare Conference
August 06, 2019 08:00 ET
|
scPharmaceuticals Inc.
BURLINGTON, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®
July 16, 2019 08:00 ET
|
scPharmaceuticals Inc.
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission and review FDA confirmed that the...
scPharmaceuticals Inc. to Present at Upcoming Investor Conferences
May 30, 2019 08:00 ET
|
scPharmaceuticals Inc.
BURLINGTON, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
May 08, 2019 08:00 ET
|
scPharmaceuticals Inc.
Type C Meeting to solidify re-filing plans for FUROSCIX® scheduled with the U.S. Food and Drug Administration (FDA) for June 2019 Resubmission of FURSOCIX New Drug Application (NDA) with the FDA in...